Influence of bodyweight on prednisolone pharmacokinetics in dogs.

Influence of bodyweight on prednisolone pharmacokinetics in dogs.

Show other versions (1)

<h4>Background</h4>Larger dogs may be at greater risk of prednisolone side effects, yet there is limited research about how bodyweight affects prednisolone pharmacokinetics in dogs.<h4>Hypothesis/objectives</h4>To describe the relationship between prednisolone dose, bodyweigh...

Full description

Saved in:
Bibliographic Details
Main Authors: Bonnie L Purcell, Andrew P Woodward, Michael G Leeming, Julien Rodolphe Samuel Dandrieux
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0326586
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<h4>Background</h4>Larger dogs may be at greater risk of prednisolone side effects, yet there is limited research about how bodyweight affects prednisolone pharmacokinetics in dogs.<h4>Hypothesis/objectives</h4>To describe the relationship between prednisolone dose, bodyweight, body surface area (BSA) and prednisolone area under the curve (AUC) in dogs receiving prednisolone for medical reasons.<h4>Animals</h4>25 client owned dogs receiving prednisolone for medical reasons.<h4>Methods</h4>Observational population pharmacokinetic study. Liquid chromatography tandem mass spectrometry was used for plasma prednisolone quantification. Data analysis was conducted in a two-stage approach using non-compartmental modelling. A Bayesian non-linear regression model described the relationship between AUC over 8 hours ([Formula: see text]ng·min/mL), bodyweight and prednisolone dose.<h4>Results</h4>From the allometric scaling model of the form AUC8h = A · BW B, the scaling exponent [Formula: see text] was.83 (90% credible interval (CrI):.60-1.06) and the coefficient [Formula: see text] was 22.8 (90% CrI: 11.8-43.4). This model suggests that equivalent exposure would be obtained using an intermediate strategy between BSA and bodyweight dosing, but the total evidence provided was relatively weak.<h4>Conclusions and clinical importance</h4>Evidence was obtained regarding the nonlinear relationship between prednisolone pharmacokinetics and bodyweight in dogs; however, this model is currently too imprecise for clinical dose determination.
ISSN:1932-6203

Similar Items